Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
87.99
+0.88 (+1.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Axsome Thera
< Previous
1
2
3
4
5
Next >
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
August 21, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
August 10, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
July 11, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
June 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
June 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
June 03, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 30, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
May 29, 2024
Data on solriamfetol featured in two oral plenary sessions
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
May 28, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
May 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 10, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
April 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 20, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.